HC Wainwright began coverage on shares of Actuate Therapeutics (NASDAQ:ACTU – Free Report) in a report released on Monday morning, Marketbeat Ratings reports. The firm issued a buy rating and a $20.00 price objective on the stock.
Actuate Therapeutics Trading Up 2.1 %
Shares of NASDAQ ACTU opened at $7.40 on Monday. Actuate Therapeutics has a 12-month low of $5.51 and a 12-month high of $11.73. The stock has a fifty day moving average price of $8.16 and a 200 day moving average price of $8.07.
Institutional Trading of Actuate Therapeutics
Several large investors have recently added to or reduced their stakes in ACTU. Freestone Capital Holdings LLC acquired a new stake in shares of Actuate Therapeutics during the fourth quarter valued at about $80,000. Envestnet Asset Management Inc. acquired a new position in Actuate Therapeutics in the fourth quarter worth about $83,000. OMERS ADMINISTRATION Corp acquired a new position in Actuate Therapeutics in the fourth quarter worth about $84,000. Sigma Planning Corp acquired a new position in Actuate Therapeutics in the fourth quarter worth about $128,000. Finally, Mercer Global Advisors Inc. ADV acquired a new position in Actuate Therapeutics in the fourth quarter worth about $130,000.
Actuate Therapeutics Company Profile
Actuate Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company’s lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer.
Featured Articles
- Five stocks we like better than Actuate Therapeutics
- How to Buy Cheap Stocks Step by Step
- Can TikTok Stock Picks Really Make You Rich?
- Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance
- The “Quality” Rotation: Back to Basics Investing
- 3 REITs to Buy and Hold for the Long Term
- Occidental Petroleum: 4 Reasons to Love These Prices
Receive News & Ratings for Actuate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actuate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.